What is Theravance Bioph's earnings per share (EPS)?

Theravance Bioph (TBPH) reported diluted earnings per share of $2.06 for fiscal year 2025. This represents a 279.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Theravance Bioph Financials

TBPH

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows Theravance Bioph (TBPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 82/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Theravance Bioph has an operating margin of -3.9%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 14/100, suggesting thin profitability after operating expenses. This is up from -72.9% the prior year.

Growth

100

Theravance Bioph's revenue surged 44.9% year-over-year to $93.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Theravance Bioph carries a low D/E ratio of 0.64, meaning only $0.64 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.93, Theravance Bioph holds $10.93 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

Theravance Bioph converts 255.6% of revenue into free cash flow ($238.5M). This strong cash generation earns a score of 100/100.

Returns

Theravance Bioph earns a strong 35.7% return on equity (ROE), meaning it generates $36 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 90/100. This is up from -32.1% the prior year.

Piotroski F-Score Neutral

6/9

Theravance Bioph passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.25x

For every $1 of reported earnings, Theravance Bioph generates $2.25 in operating cash flow ($238.5M OCF vs $105.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

-1.5x

Theravance Bioph earns $-1.5 in operating income for every $1 of interest expense (-$3.6M vs $2.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$93.3M

YoY+44.9%

5Y CAGR+5.4%

10Y CAGR+8.3%

Theravance Bioph generated $93.3M in revenue in fiscal year 2025. This represents an increase of 44.9% from the prior year.

EBITDA

-$2.1M

YoY+95.4%

Theravance Bioph's EBITDA was -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 95.4% from the prior year.

Net Income

$105.9M

YoY+287.7%

Theravance Bioph reported $105.9M in net income in fiscal year 2025. This represents an increase of 287.7% from the prior year.

EPS (Diluted)

$2.06

YoY+279.1%

Theravance Bioph earned $2.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 279.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$238.5M

YoY+2109.8%

Theravance Bioph generated $238.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2109.8% from the prior year.

Cash & Debt

$167.8M

YoY+344.0%

5Y CAGR+15.5%

10Y CAGR+4.1%

Theravance Bioph held $167.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

51M

YoY+4.1%

5Y CAGR-4.4%

10Y CAGR+3.1%

Theravance Bioph had 51M shares outstanding in fiscal year 2025. This represents an increase of 4.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-3.9%

YoY+69.1pp

5Y CAGR+410.3pp

10Y CAGR+427.9pp

Theravance Bioph's operating margin was -3.9% in fiscal year 2025, reflecting core business profitability. This is up 69.1 percentage points from the prior year.

Net Margin

113.5%

YoY+201.1pp

5Y CAGR+500.4pp

10Y CAGR+546.0pp

Theravance Bioph's net profit margin was 113.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 201.1 percentage points from the prior year.

Return on Equity

35.7%

YoY+67.8pp

10Y CAGR+110.7pp

Theravance Bioph's ROE was 35.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 67.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$37.4M

YoY-0.6%

5Y CAGR-32.2%

10Y CAGR-11.7%

Theravance Bioph invested $37.4M in research and development in fiscal year 2025. This represents a decrease of 0.6% from the prior year.

Share Buybacks

$445K

YoY+0.0%

Theravance Bioph spent $445K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 0.0% from the prior year.

Capital Expenditures

$42K

YoY-87.3%

5Y CAGR-63.6%

10Y CAGR-33.9%

Theravance Bioph invested $42K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 87.3% from the prior year.

TBPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$93.3M+44.9%	$64.4M+12.1%	$57.4M+11.8%	$51.3M-7.2%	$55.3M-23.0%	$71.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$37.4M-0.6%	$37.6M-7.3%	$40.6M-35.9%	$63.4M-67.3%	$193.7M-25.8%	$261.0M
SG&A Expenses	$73.7M+6.5%	$69.2M-1.3%	$70.1M+4.5%	$67.1M-32.5%	$99.3M-8.5%	$108.5M
Operating Income	-$3.6M+92.3%	-$46.9M+16.2%	-$56.0M+39.1%	-$92.0M+64.3%	-$257.8M+13.4%	-$297.6M
Interest Expense	$2.5M-3.3%	$2.5M+8.3%	$2.4M-63.1%	$6.4M-25.5%	$8.5M0.0%	$8.5M
Income Tax	$23.4M+97.8%	$11.8M+99.3%	$5.9M+65722.2%	$9K+106.0%	-$151K+98.2%	-$8.5M
Net Income	$105.9M+287.7%	-$56.4M-2.2%	-$55.2M-106.3%	$872.1M+537.3%	-$199.4M+28.3%	-$278.0M
EPS (Diluted)	$2.06+279.1%	$-1.15-15.0%	$-1.00-108.4%	$11.85+512.9%	$-2.87+35.7%	$-4.46

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$20.0M-23.7%	$26.2M+70.2%	$15.4M-17.9%	$18.8M+11.2%	$16.9M+18.3%	$14.3M-1.7%	$14.5M-17.4%	$17.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$8.1M-22.7%	$10.5M-8.4%	$11.5M	N/A	$9.3M-6.9%	$10.0M+11.0%	$9.0M	N/A
SG&A Expenses	$18.3M-0.5%	$18.4M+0.3%	$18.4M	N/A	$16.9M-1.1%	$17.1M+1.9%	$16.7M	N/A
Operating Income	-$6.5M-136.9%	-$2.7M+81.1%	-$14.4M-56.9%	-$9.2M+15.1%	-$10.8M+31.0%	-$15.7M-40.1%	-$11.2M-79.6%	-$6.2M
Interest Expense	$573K-13.6%	$663K+3.1%	$643K	N/A	$630K-2.2%	$644K+2.4%	$629K	N/A
Income Tax	-$6.5M-135.4%	$18.4M+3386.4%	-$559K	N/A	$2.6M+102.3%	$1.3M+3.6%	$1.3M	N/A
Net Income	$3.6M-93.4%	$54.8M+503.8%	-$13.6M+12.5%	-$15.5M-22.3%	-$12.7M+23.2%	-$16.5M-41.7%	-$11.7M-37.1%	-$8.5M
EPS (Diluted)	$0.07-93.5%	$1.08+500.0%	$-0.27+12.9%	$-0.31-19.2%	$-0.26+23.5%	$-0.34-41.7%	$-0.24-41.2%	$-0.17

TBPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$485.6M+37.1%	$354.2M-7.3%	$382.0M-37.1%	$607.4M+62.1%	$374.8M-20.1%	$469.1M
Current Assets	$418.5M+159.8%	$161.1M+20.6%	$133.5M-62.2%	$353.5M+41.5%	$249.9M-36.5%	$393.3M
Cash & Equivalents	$167.8M+344.0%	$37.8M-4.4%	$39.5M-86.7%	$298.2M+231.5%	$90.0M+10.4%	$81.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$188.8M+5.7%	$178.6M+5.7%	$169.0M+2.1%	$165.6M-76.8%	$713.4M-7.7%	$772.8M
Current Liabilities	$38.3M+19.4%	$32.1M+29.5%	$24.8M-13.7%	$28.7M-51.0%	$58.6M-52.6%	$123.6M
Long-Term Debt	N/A	N/A	$0	N/A	$616.3M-0.5%	$619.2M
Total Equity	$296.7M+69.0%	$175.5M-17.6%	$213.0M-51.8%	$441.8M+230.5%	-$338.6M-11.5%	-$303.8M
Retained Earnings	-$859.6M+11.0%	-$965.5M-6.2%	-$909.1M-6.5%	-$853.9M+50.5%	-$1.7B-13.1%	-$1.5B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$415.5M-2.5%	$426.0M+24.0%	$343.6M-3.0%	$354.2M-0.5%	$356.1M-1.6%	$362.0M-2.5%	$371.3M-2.8%	$382.0M
Current Assets	$354.7M-3.2%	$366.3M+143.8%	$150.3M-6.7%	$161.1M+38.3%	$116.5M-2.4%	$119.3M-4.0%	$124.3M-6.9%	$133.5M
Cash & Equivalents	$174.8M-38.0%	$281.9M+154.9%	$110.6M+192.7%	$37.8M+61.7%	$23.4M-49.6%	$46.3M-13.9%	$53.8M+36.1%	$39.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$182.8M-9.1%	$201.2M+13.3%	$177.6M-0.6%	$178.6M+4.8%	$170.5M+1.3%	$168.3M+1.1%	$166.4M-1.5%	$169.0M
Current Liabilities	$37.4M-31.5%	$54.6M+73.4%	$31.5M-1.8%	$32.1M+36.9%	$23.4M+2.1%	$22.9M+5.9%	$21.7M-12.5%	$24.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$232.7M+3.5%	$224.8M+35.5%	$166.0M-5.4%	$175.5M-5.4%	$185.7M-4.1%	$193.7M-5.5%	$204.9M-3.8%	$213.0M
Retained Earnings	-$920.7M+0.4%	-$924.3M+5.6%	-$979.1M-1.4%	-$965.5M-1.6%	-$950.0M-1.4%	-$937.3M-1.8%	-$920.8M-1.3%	-$909.1M

TBPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$238.5M+2168.0%	-$11.5M+57.3%	-$27.0M+85.6%	-$187.0M+10.0%	-$207.9M+17.0%	-$250.4M
Capital Expenditures	$42K-87.3%	$332K-86.7%	$2.5M+335.0%	$572K-83.2%	$3.4M-48.5%	$6.6M
Free Cash Flow	$238.5M+2109.8%	-$11.9M+59.8%	-$29.5M+84.3%	-$187.6M+11.2%	-$211.3M+17.8%	-$257.0M
Investing Cash Flow	-$105.3M-957.1%	$12.3M+137.6%	-$32.7M-102.8%	$1.2B+827.0%	$124.5M+1061.2%	$10.7M
Financing Cash Flow	-$3.2M-30.1%	-$2.5M+98.7%	-$198.9M+73.8%	-$758.8M-926.0%	$91.9M-65.1%	$263.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$445K0.0%	$445K-99.8%	$197.1M+53.0%	$128.8M	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.5M-103.1%	$208.1M+383.5%	$43.0M+4871.5%	-$902K+82.6%	-$5.2M-17.7%	-$4.4M-332.0%	-$1.0M-19.7%	-$854K
Capital Expenditures	$0	N/A	N/A	$190K+1166.7%	$15K-58.3%	$36K-60.4%	$91K-86.6%	$677K
Free Cash Flow	-$6.5M	N/A	N/A	-$1.1M+79.0%	-$5.2M-17.1%	-$4.5M-299.9%	-$1.1M+27.3%	-$1.5M
Investing Cash Flow	-$100.2M-176.5%	-$36.3M-218.4%	$30.6M+95.3%	$15.7M+190.2%	-$17.4M-474.0%	-$3.0M-117.8%	$17.0M+2615.2%	-$677K
Financing Cash Flow	-$400K+20.5%	-$503K+41.1%	-$854K-134.0%	-$365K+1.9%	-$372K-745.5%	-$44K+97.4%	-$1.7M+94.4%	-$30.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0	$0-100.0%	$445K-98.5%	$30.3M

TBPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-3.9%+69.1pp	-72.9%+24.7pp	-97.6%+81.5pp	-179.1%+287.0pp	-466.1%-51.9pp	-414.2%
Net Margin	113.5%+201.1pp	-87.6%+8.5pp	-96.1%-1794.6pp	1698.5%+2059.1pp	-360.6%+26.4pp	-386.9%
Return on Equity	35.7%+67.8pp	-32.1%-6.2pp	-25.9%-223.3pp	197.4%	N/A	N/A
Return on Assets	21.8%+37.7pp	-15.9%-1.5pp	-14.4%-158.0pp	143.6%+196.8pp	-53.2%+6.1pp	-59.3%
Current Ratio	10.93+5.9	5.02-0.4	5.39-6.9	12.31+8.0	4.26+1.1	3.18
Debt-to-Equity	0.64-0.4	1.02+1.0	0.00-0.4	0.37+2.2	-1.82+0.2	-2.04
FCF Margin	255.6%+274.0pp	-18.4%+32.9pp	-51.3%+313.9pp	-365.3%+16.7pp	-382.0%-24.3pp	-357.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-32.3%-21.9pp	-10.4%+83.4pp	-93.8%-44.7pp	-49.1%+15.2pp	-64.3%+45.9pp	-110.2%-32.9pp	-77.3%-41.7pp	-35.5%
Net Margin	18.1%-191.3pp	209.3%+297.6pp	-88.2%-5.4pp	-82.8%-7.5pp	-75.3%+40.7pp	-115.9%-35.5pp	-80.4%-32.0pp	-48.4%
Return on Equity	1.6%-22.8pp	24.4%+32.6pp	-8.2%+0.7pp	-8.8%-2.0pp	-6.8%+1.7pp	-8.5%-2.8pp	-5.7%-1.7pp	-4.0%
Return on Assets	0.9%-12.0pp	12.9%+16.8pp	-4.0%+0.4pp	-4.4%-0.8pp	-3.6%+1.0pp	-4.6%-1.4pp	-3.1%-0.9pp	-2.2%
Current Ratio	9.48+2.8	6.70+1.9	4.77-0.3	5.02+0.0	4.97-0.2	5.20-0.5	5.74+0.3	5.39
Debt-to-Equity	0.79-0.1	0.89-0.2	1.07+0.1	1.02+0.1	0.92+0.0	0.87+0.1	0.81+0.8	0.00
FCF Margin	-32.6%	N/A	N/A	-5.8%+25.1pp	-30.9%+0.3pp	-31.2%-23.5pp	-7.7%+1.0pp	-8.7%

Similar Companies

Day One Biopharmaceuticals, Inc. DAWN

$2.2B

Relay Therapeutics, Inc. RLAY

$2.2B

Nurix Therapeutics, Inc. NRIX

$1.6B

Rezolute Inc RZLT

$298.6M

Rigel Pharmaceuticals Inc RIGL

$508.6M

Frequently Asked Questions

What is Theravance Bioph's annual revenue?

Theravance Bioph (TBPH) reported $93.3M in total revenue for fiscal year 2025. This represents a 44.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Theravance Bioph's revenue growing?

Theravance Bioph (TBPH) revenue grew by 44.9% year-over-year, from $64.4M to $93.3M in fiscal year 2025.

Is Theravance Bioph profitable?

Yes, Theravance Bioph (TBPH) reported a net income of $105.9M in fiscal year 2025, with a net profit margin of 113.5%.

What is Theravance Bioph's EBITDA?

Theravance Bioph (TBPH) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Theravance Bioph's operating margin?

Theravance Bioph (TBPH) had an operating margin of -3.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Theravance Bioph's net profit margin?

Theravance Bioph (TBPH) had a net profit margin of 113.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Theravance Bioph's return on equity (ROE)?

Theravance Bioph (TBPH) has a return on equity of 35.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Theravance Bioph's free cash flow?

Theravance Bioph (TBPH) generated $238.5M in free cash flow during fiscal year 2025. This represents a 2109.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Theravance Bioph's operating cash flow?

Theravance Bioph (TBPH) generated $238.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Theravance Bioph's total assets?

Theravance Bioph (TBPH) had $485.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Theravance Bioph's capital expenditures?

Theravance Bioph (TBPH) invested $42K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Theravance Bioph spend on research and development?

Theravance Bioph (TBPH) invested $37.4M in research and development during fiscal year 2025.

Does Theravance Bioph buy back shares?

Yes, Theravance Bioph (TBPH) spent $445K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Theravance Bioph have outstanding?

Theravance Bioph (TBPH) had 51M shares outstanding as of fiscal year 2025.

What is Theravance Bioph's current ratio?

Theravance Bioph (TBPH) had a current ratio of 10.93 as of fiscal year 2025, which is generally considered healthy.

What is Theravance Bioph's debt-to-equity ratio?

Theravance Bioph (TBPH) had a debt-to-equity ratio of 0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Theravance Bioph's return on assets (ROA)?

Theravance Bioph (TBPH) had a return on assets of 21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Theravance Bioph's Piotroski F-Score?

Theravance Bioph (TBPH) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Theravance Bioph's earnings high quality?

Theravance Bioph (TBPH) has an earnings quality ratio of 2.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Theravance Bioph cover its interest payments?

Theravance Bioph (TBPH) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Theravance Bioph?

Theravance Bioph (TBPH) scores 82 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.